ORKA (Oruka Therapeutics) Pretax Margin % : % (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Oruka Therapeutics's Pre-Tax Income for the six months ended in Mar. 2024 was $0.00 Mil. Oruka Therapeutics's Revenue for the six months ended in Mar. 2024 was $0.00 Mil. Therefore, Oruka Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Oruka Therapeutics's Pretax Margin % or its related term are showing as below:

ORKA's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -137.15
* Ranked among companies with meaningful Pretax Margin % only.

Oruka Therapeutics Pretax Margin % Historical Data

The historical data trend for Oruka Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Pretax Margin % Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Pretax Margin %

Oruka Therapeutics Semi-Annual Data
	Mar24
Pretax Margin %	-

Competitive Comparison of Oruka Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Oruka Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Pretax Margin % falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Oruka Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	0	/	0
	=	%

Oruka Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=	%

Oruka Therapeutics (NAS:ORKA) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Oruka Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.